---
title: "Precigen 10% Owner Randal Kirk Sold About $45.1M After PAPZIMEOS Won FDA Approval"
type: news
slug: randal-kirk-sold-45m-precigen-after-papzimeos-approval
canonical_url: https://13finsight.com/news/randal-kirk-sold-45m-precigen-after-papzimeos-approval
published_at: 2026-03-06T17:34:53.426Z
updated_at: 2026-03-23T07:04:21.852Z
author: Alex Rivera
author_title: Breaking News Editor
author_url: https://13finsight.com/authors/alex-rivera
word_count: 382
locale: en
source: 13F Insight
---

# Precigen 10% Owner Randal Kirk Sold About $45.1M After PAPZIMEOS Won FDA Approval

> Randal Kirk's September-to-December Precigen selling followed a major corporate milestone: FDA approval of PAPZIMEOS, the company's first approved product in the U.S., and new long-term follow-up messaging around the platform.

Randal J. Kirk, a 10% owner of Precigen, sold about $45.1 million of stock across a September-to-December 2025 window. The context is what makes the tape interesting. In August 2025, Precigen announced full FDA approval of PAPZIMEOS for adults with recurrent respiratory papillomatosis, turning the company into a commercial-stage biotech with its first approved product in the U.S. The company then highlighted long-term follow-up results on the same platform. That means Kirk was selling after a major de-risking event, not ahead of one. The Selling Window DateShares SoldEstimated ValueContext 2025-09-18 to 2025-09-306.81M~$24.8MLarge post-approval monetization wave 2025-11-19 to 2025-11-212.97M~$12.3MSecond major sale cluster 2025-12-221.90M~$7.9MFinal highlighted 2025 sale day Total highlighted sales11.68M+~$45.1MWhile still retaining a multi-million-share stake Why This Matters Precigen's own website now centers the PAPZIMEOS approval as a defining milestone and points investors to the FDA announcement and long-term follow-up materials. That is a very different setup from a speculative pre-approval biotech story. Kirk's sales came after the company crossed a major regulatory threshold and started presenting itself as a commercial-stage medicine company. That shifts the frame. Investors should not read this as a binary “insider knows bad news” pattern. It looks more like a large holder monetizing after a dramatic reduction in regulatory uncertainty. Why Retail Investors Should Still Pay Attention Biotech insiders and large holders often sell after clinical or regulatory wins because liquidity finally appears. But the size here is still material enough to matter. Selling $45.1 million in a few months is not token diversification. For investors in event-driven biotech names such as CRISPR Therapeutics, Intellia, Editas, or diagnostics-growth names like Guardant Health, the lesson is the same: post-catalyst insider behavior helps separate “milestone monetization” from ongoing insider accumulation. Key Facts MetricValue InsiderRandal J. Kirk CompanyPrecigen (PGEN) Highlighted sale windowSep. 18, 2025 to Dec. 22, 2025 Estimated value sold~$45.1M Major backdrop eventFDA approval of PAPZIMEOS in August 2025 Platform backdropCompany later highlighted long-term follow-up results What To Watch Further 10% owner sales: Another wave after the approval cycle would change the tone. Commercial uptake: The approval matters less if PGEN cannot translate it into durable commercialization. Biotech context: Compare insider behavior in PGEN with peers like CRSP, NTLA, EDIT, and GH. Signal hygiene: For framework, read our Form 4 explainer, our combined 13F/Form 4 guide, and our comparison guide.

---

Source: 13F Insight — https://13finsight.com/news/randal-kirk-sold-45m-precigen-after-papzimeos-approval
Author: Alex Rivera — https://13finsight.com/authors/alex-rivera
Last updated: 2026-03-23T07:04:21.852Z